Earnings Feed
Start Free
Solid Biosciences Inc.·4

Feb 2, 8:16 PM ET

Cumbo Alexander 4

Research Summary

AI-generated summary

Updated

Solid Biosciences (SLDB) CEO Alexander Cumbo Sells 80,258 Shares

What Happened
Alexander Cumbo, President, CEO and a director of Solid Biosciences (SLDB), sold 80,258 common shares in an open‑market transaction on Feb 2, 2026 for a weighted average price of $6.44, generating $516,613. Around the same time (Jan 29 and Jan 31, 2026) Cumbo converted/exercised derivative awards: 169,401 shares on Jan 29 and 100,400 shares on Jan 31, and received award grants on Jan 29 totaling 764,750 units (509,850 and 254,900). Many of these entries reflect PSU/RSU conversions and option activity rather than independent cash purchases.

Key Details

  • Transaction dates: Jan 29, 2026 (derivative conversions and awards), Jan 31, 2026 (derivative conversion), Feb 2, 2026 (open‑market sale).
  • Sale price/value: weighted average $6.44; gross proceeds reported $516,613. Sales occurred at prices ranging $6.295–$6.580 (per filing footnote).
  • Shares involved: 80,258 shares sold; conversions/exercises totaling 269,801 shares (169,401 + 100,400); awards granted on Jan 29 totaling 764,750 units.
  • Reason for sale: sell‑to‑cover to satisfy withholding taxes after PSU vesting (durable automatic sell‑to‑cover instruction adopted Aug 18, 2024). The filing states the sale was not a discretionary trade. (See footnote F3.)
  • Derivative/award details: PSUs convert 1:1 to common stock (F1); RSUs convert 1:1 (F2); a performance milestone certified Jan 29, 2026 caused 25% of certain PSUs to vest (F5). Option and RSU grants vest over four years (F6, F7).
  • Shares owned after transaction: not specified in the provided excerpt.
  • Filing timeliness: no late filing flag indicated in the excerpt.

Context

  • Codes: S = sale, M = exercise/conversion of derivative, A = grant/award. The Jan conversions reflect settlement/vesting of equity derivatives (PSUs/RSUs or option conversions), not a market purchase.
  • The open‑market sale was a routine sell‑to‑cover tied to tax withholding after awards vested rather than an independent, discretionary sale by the CEO. Such transactions commonly reflect tax logistics rather than a signal of sentiment.
  • If you want the precise per‑trade breakdown within the reported price range, the filer has offered to provide that detail upon request (per footnote F4).